Skip to main content
TipRanks
Go Ultimate75% OFF

Infant Bacterial Therapeutics AB (IBT.B) AI Stock Analysis

0 Followers
SE:IBT.B

Infant Bacterial Therapeutics AB

(Nasdaq OMX AB:IBT.B)

Select Model
Rating:41Neutral
Price Target:SEK 63.00â–¼(-11.27% Downside)
Action:upgraded
Date:11/14/26

The overall score is severely constrained by the company's pre-revenue status and deep losses, which present a critical financial risk. The rapidly depleting cash and equity reserves, despite a reduced burn rate, are a major concern. Technicals are neutral and do not offset the fundamental weaknesses, while the negative P/E ratio confirms a lack of traditional value.

Positive Factors
Debt-free balance sheetA debt-free capital structure limits interest expense and solvency pressure while the company funds clinical development. This gives management greater flexibility than a leveraged peer if additional financing, partnering, or commercialization opportunities become available.
Negative Factors
No current revenueWith no current revenue, the business has not yet demonstrated commercial demand or recurring operating income from its candidates. Its ability to create durable value therefore remains dependent on future clinical, regulatory, and commercialization success.

Infant Bacterial Therapeutics AB (IBT.B) vs. iShares MSCI Sweden ETF (EWD)

-20%0%20%40%60%80%SE:IBT.B+40.87%EWD+12.46%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 956.47M
Dividend Yield
―
Average Volume (3M)
9,973
Price to Earnings (P/E)
-10.3
Beta (1Y)
-0.52
Revenue Growth
―
EPS Growth
-15.81%
Country
Sweden
Employees
6
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Infant Bacterial Therapeutics AB Business Overview & Revenue Model

Company Description

Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is...

How the Company Makes Money

Infant Bacterial Therapeutics AB is a clinical-stage biotechnology company and, based on publicly available information, it has not been characterized as generating material recurring revenue from product sales. Its primary economic model is to inves...

Infant Bacterial Therapeutics AB Financial Statement Overview

Summary

The company is pre-revenue with substantial net losses, making the income statement extremely weak. The balance sheet is debt-free but equity is eroding rapidly, and cash flow is negative, though the burn rate has improved. Overall financial health is poor and high-risk, typical of early-stage biotech but with a limited cash runway.

Income Statement

1Very Negative

Balance Sheet

55Neutral

Cash Flow

20Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue004,00077.00K12.00K0
Gross Profit004,00077.00K12.00K0
EBITDA-82.02M-68.18M-136.09M-122.25M-64.34M-43.76M
Net Income-81.92M-65.17M-136.91M-123.07M-65.45M-44.99M
Balance Sheet
Total Assets120.22M161.75M239.57M351.33M349.62M408.48M
Cash, Cash Equivalents and Short-Term Investments108.60M144.01M223.39M329.06M335.84M386.75M
Total Debt000000
Total Liabilities67.20M56.42M69.30M46.18M17.91M13.22M
Stockholders Equity53.02M105.33M170.26M305.15M331.71M395.25M
Cash Flow
Free Cash Flow-64.06M-72.34M-113.13M-101.22M-85.80M-55.62M
Operating Cash Flow-64.06M-72.34M-113.13M-101.22M-85.80M-55.62M
Investing Cash Flow000-4.15M-1,0000
Financing Cash Flow002.01M96.52M1.88M91.00K

Infant Bacterial Therapeutics AB Technical Analysis

Technical Analysis SentimentPositive
Last Price71.00

Price Trends

50DMA71.58Negative
100DMA68.59Positive
200DMA61.72Positive

Market Momentum

MACD-0.91Positive
RSI48.96Neutral
STOCH59.52Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:IBT.B, the sentiment is Positive. The current price of 71.00 is below the 20-day moving average (MA) of 71.67, below the 50-day MA of 71.58, and above the 200-day MA of 61.72, indicating a neutral trend. The MACD of -0.91 indicates Positive momentum. The RSI at 48.96 is Neutral, neither overbought nor oversold. The STOCH value of 59.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:IBT.B.

Infant Bacterial Therapeutics AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SE:IBT.B against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:HNSASE:HNSA60NeutralSEK 4.82B-5.99――68.88%10.63%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:BINVSE:BINV49NeutralSEK 142.80M-0.29-128.54%―-83.67%-50.29%
SE:XBRANESE:XBRANE46NeutralSEK 219.45M-5.89-11.52%―-38.80%-120.18%
SE:IBT.BSE:IBT.B41NeutralSEK 956.47M-10.35-134.93%――-15.81%
SE:EXPRS2SE:EXPRS238UnderperformSEK 37.57M-0.23-109.57%―26.88%61.44%
SE:IVACCSE:IVACC38UnderperformSEK 231.07M-2.25-43.10%―-17.73%18.97%

* Healthcare Sector Average

Performance Comparison

-50%0%50%SE:IBT.BSE:HNSASE:BINVSE:XBRANESE:IVACCSE:EXPRS2Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:IBT.B and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:IBT.BInfant Bacterial Therapeutics71.0017.6032.96%
SE:HNSAHansa Biopharma47.3219.3469.12%
SE:BINVBioInvent International AB2.17-27.13-92.59%
SE:XBRANEXbrane Biopharma AB10.651.9422.20%
SE:IVACCIntervacc AB0.68-0.22-24.16%
SE:EXPRS2ExpreS2ion Biotech Holding AB0.95-5.48-85.19%

Infant Bacterial Therapeutics AB Corporate Events

IBT Reports No Sales as IBP-9414 Manufacturing Validation Completes

Nov 13, 2026

Infant Bacterial Therapeutics AB is a pharmaceutical developer of IBP-9414, a therapeutic administered to infants, with an EU Orphan Drug Designation for the product. During the nine months ended September 30, 2026, the company reported no net sales...

IBT Reports No Refusal-to-File Issues at FDA Pre-BLA Meeting

Nov 2, 2026

Infant Bacterial Therapeutics AB is a pharmaceutical company focused on developing treatments for premature infants, led by IBP-9414, a live biotherapeutic product designed to address serious neonatal diseases. The company’s portfolio also includes c...

IBT Secures FDA Pre-BLA Meeting for Breakthrough Neonatal Therapy

Sep 21, 2026

Infant Bacterial Therapeutics AB, a Stockholm-based pharmaceutical company listed on Nasdaq Stockholm, specializes in therapies for premature infants, led by its live biotherapeutic candidate IBP-9414 derived from bacteria in human breast milk. The f...

Infant Bacterial Therapeutics Sets Nomination Committee Ahead of 2027 AGM

Sep 18, 2026

Infant Bacterial Therapeutics AB has appointed its Nomination Committee for the 2027 Annual General Meeting, in line with its established governance framework and based on the ownership structure as of June 30, 2026. The committee includes representa...

Infant Bacterial Therapeutics Advances IBP-9414 Toward Market Despite Wider Losses

Aug 26, 2026

Infant Bacterial Therapeutics AB reported no net sales for the first half of 2026 and a widened operating loss, reflecting its pre-commercial stage as it advances its lead neonatal drug candidate IBP-9414 toward market approval. Despite the financial...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 14, 2026